Business Wire

WA-SCHULTZ-FAMILY-FND

13.2.2024 21:54:28 CET | Business Wire | Press release

Share
Trilogy Films and the Schultz Family Foundation Join Forces to Chronicle the Untold Story of Nelson and Winnie Mandela

Trilogy Films, the renowned production company led by award-winning Director Dawn Porter, is thrilled to announce an unprecedented collaboration with the Schultz Family Foundation to produce a feature-length documentary about one of the most iconic, politically-charged partnerships in history: the remarkable, largely untold story of Nelson and Winnie Mandela.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240212248716/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Nelson and Winnie Mandela after his liberation from prison in South Africa on February 11, 1990. Photo by Pool BOUVET/DE KEERLE/Gamma-Rapho via Getty Images.

Based on the book by noted South African writer and scholar Jonny Steinberg, Winnie and Nelson: Portrait of a Marriage, the film will explore the Mandelas’ profound bond and how their marriage was inextricably entangled with the struggle against apartheid. The film promises an intimate portrayal of Nelson and Winnie’s marriage, delving into their vehement and volatile connection from their early years to their mutual goal of dismantling apartheid. Their journey culminates in Nelson Mandela’s historic election as South Africa’s first democratically elected President. This cinematic exploration captures the essence of their indomitable spirits and the global impact of their love and advocacy.

Dawn Porter, celebrated for her exceptional storytelling that explores the overlooked, reveals the consequences of policy and social action, champions the marginalized, and offers a fresh perspective on the familiar, is at the helm of the production. With her profound ability to craft narratives that deeply resonate with and inform audiences, Porter is poised to bring a unique lens to the enduring love story of Nelson and Winnie Mandela.

“Creating a film about Nelson Mandela’s life is an extraordinary privilege, and I am genuinely thrilled about the collaboration with the Schultz Family Foundation and Trilogy Films,” said Dawn Porter. “Nelson Mandela’s journey exemplifies the resilience and capacity for change within the human spirit. We aspire to share this incredible odyssey with audiences around the globe. But his story is incomplete without exploring the relationship with his most influential and intimate advisor – his wife Winnie. There can be no definitive Mandela story without understanding the complicated dynamics of their relationship.”

The collaboration with Trilogy Films marks the Schultz Family Foundation’s first venture into transformative storytelling projects – across scripted and documentary films and series, podcasts, and books – linked to its mission of creating greater opportunity, accessible to all. The Schultz Family Foundation’s involvement transcends financial support; it embodies a philanthropic vision and commitment to tell truthful, aspirational stories that have the power to reveal hidden narratives, spark hope, spotlight solutions, and restore confidence during a time of enormous pessimism, dissension, misinformation, and a fracturing of trust in traditional institutions, leadership, and each other.

“At its heart, Winnie and Nelson is a complicated story of leadership, conflict, love, and extraordinary sacrifice in the face of unfathomable brutality where the future of a democracy was at stake,” said Howard Schultz, co-founder of the Schultz Family Foundation and chairman emeritus of Starbucks Corporation. “My wife Sheri and I feel privileged and humbled by the opportunity to partner with such a respected and talented director as Dawn to bring this film to life. We believe in the power of human-centered, aspirational storytelling to nurture our common bonds, foster our shared humanity, and inspire the next generation of leaders, and we look forward to pursuing other projects across many different formats aligned with our family’s philanthropic work and mission.”

About Trilogy Films:

Trilogy Films, founded by award-winning director Dawn Porter, directs and produces non-fiction content that tells untold stories, shares new perspectives, and reveals the complex humanity of some of history’s most iconic figures. Porter's acclaimed films include "Gideon’s Army" (2013), "Spies of Mississippi” (2014), and “Bobby Kennedy for President” (2018). Her latest work, “Luther: Never Too Much,” debuted to rave reviews at the 2024 Sundance Film Festival and was lauded as the best of fest in multiple news outlets. 2023 was a banner year for Porter and Trilogy. The Critics Choice nominated “Lady Bird Diaries," an all archival documentary showcasing Lady Bird Johnson, premiered at the 2023 SXSW Film Festival, while her four-part docuseries "Deadlocked: How America Shaped the Supreme Court” also garnered nominations for a Critics Choice Documentary Award as well as a Film Independent Spirit Award.

About the Schultz Family Foundation:

The Schultz Family Foundation’s mission is to create greater opportunity, accessible to all. Our work is deeply rooted in the lives and values of our co-founders, Sheri and Howard Schultz, who believe talent is everywhere, but opportunity is not. We seek to apply the lessons they have learned over the decades to seed innovations and scale solutions to help young people successfully navigate the transition to adulthood and positively impact the trajectory of their lives. We are investors in unleashing potential and unlocking opportunity, working in partnership with employers, entrepreneurs, non-profits, and governments that share our aspiration of enabling everyone to access the full promise of America. For more information about the Foundation and its work: www.schultzfamilyfoundation.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240212248716/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye